Zensun Sci & Tech, Ltd., a biopharmaceutical company based in Shanghai and San Diego, announced today positive results of four completed Phase 2 clinical trials including three double-blind, placebo-controlled studies conducted in China and Australia and interim results from the United States Phase 2 trial for Zensun’s innovative “first-in-class” anti-heart failure drug, Neucardin™.
To view Multimedia News Release, go to http://www.multivu.com/mnr/61677-zensun-completes-clinical-trials-of-neucardin-treatment-of-heart-failure
You Can Get The Full FREE Info Now - https://bit.ly/3stNQ4z
Watch Video Here - https://bit.ly/3tXCgis
Hello, I'm Dr Khatri
As always, helping you stay loved, stay healthy and stay wealthy..
Today we are talking about the #1 method to help support a healthy prostate.
Since numerous long stretches of individual preliminaries and tests, I accept that they have at last found an uncommon mix of fixings which may help anybody support a healthy prostate.
The accompanying equation is determined and acclimated to give THE BEST POSSIBLE RESULTS with regards to help keeping up the great wellbeing of your enlarged prostate.
https://www.youtube.com/watch?v=d5lwVizFwl8
The Preeclampsia Foundation, the nation’s only non-profit patient advocacy organization for preeclampsia and related hypertensive disorders of pregnancy, today announced the results of a recent nationwide Preeclampsia Awareness Survey of more than 1,500 expectant and new mothers. These findings are driving the Foundation’s strategies associated with National Preeclampsia Awareness Month.
To view the Multimedia News Release, go to: http://www.multivu.com/mnr/7171451-preeclampsia-foundation-awareness-survey-education-pregnancy-disorders
Results from a large retrospective data analysis published in the American Journal of Transplantation (AJT) today, showed that liver transplantation patients who were treated early with Advagraf experienced a significantly increased graft survival benefit of 8% at 3 years post-transplant compared with patients treated with the current standard of care, tacrolimus immediate release (twice daily).
To view the Multimedia News Release, go to: http://www.multivu.com/players/English/7451251-advagraf-prolonged-release-tacrolimus/
Chiasma, Inc., a U.S. privately–held biopharma company developing octreotide capsules for the orphan condition acromegaly, today announced two new studies presented at the 97th Endocrine Society (ENDO) Annual Meeting in San Diego, Calif. The studies provide additional data from Chiasma’s Phase III trial and new findings on the patient burden of current injection therapies.
“We now have data to help clinicians determine whether octreotide capsules, if approved, are likely to help their patient with acromegaly maintain response,” said Shlomo Melmed, M.D., senior vice president and dean, Cedars–Sinai Medical Center, Los Angeles and global study principal investigator. “Furthermore, the Phase III results show the safety and efficacy of octreotide capsules can be reliably determined within 12 weeks of initiating therapy.”
To view the Multimedia News Release, go to http://www.multivu.com/players/English/7436451-endo-chiasma-clinical-data/
On World Mental Health Day, Janssen has announced the results of a pan-European research project: ‘Talking About Treatment in Schizophrenia: A Patient and Carer Survey’. The survey of 166 adults living with schizophrenia and 468 carers was conducted by the independent market research agency, Fieldwork International (part of Ipsos MORI), and explored awareness, feelings and preferences regarding treatment.
The survey, conducted across 12 countries in Europe (Austria, Belgium, Denmark, France, Germany, Italy, Netherlands, Russia, Spain, Sweden, Switzerland and the UK), highlighted key factors affecting the peace of mind for carers, such as the impact of the condition on day‑to-day life, potential relapse/hospitalisation and getting support beyond medication. 94% stated they reminded the person they care for to take their medication and for 49% this happens often.
To view the multimedia release go to:
http://www.multivu.com/players/uk/7947151-janssen-survey-carers-adults-schizophrenia/
http://www.myweightlosssolutions.com
kettering weight loss solutions - kettering weight loss solutions - treating chronic conditio
Top Tips kettering weight loss solutions whipp road
for weight loss do they work :-) Appetite Suppressant - Garcinia Cambogia 1300 - Natural Fat Burner -2B 120Ct with alternate day fasting weight loss results
Also, learn about natural supplements that are sometimes recommended in alternative medicine for weight loss
OPTIFAST® as an Alternative to Weight Loss Surgery 20 Healthy Food Alternatives For Weight Loss
Looking for alternatives to weight loss surgery
Alternate day fasting weight loss calculator
Kettering weight loss solutions - transform your life.
You Should Know About It kettering weight loss solutions whipp road,Fat Burning Kitchen - REVIEW.
2018 - A new study found that you can use alternate day fasting to lose weight and still eat on your fast day alternate day fasting weight loss results.
Check out this alternate day fasting weight loss technique.
Before you do, here are some alternatives to weight loss surgery.
Food list; Healthy junk food recipes; Healthy food substitutes; Junk foods that are actually healthy; Healthy food alternatives for weight loss.
Risk factors, many individuals seeking effective weight loss programs find Cenegenics to be an attractive alternative to weight loss surgery.
2018 - Researchers develop pill alternative to weight loss surgery.
The tapping solution weight loss and body confidence.
Metabolic weight loss solutions reviews.
Beck diet solution weight loss workbook.
Medical weight loss solutions birmingham.
Results from a new national survey released today indicate that our lifestyle exacerbates the challenge of trying to lose weight, making it more difficult than ever for adults to do so. Findings further suggest that adults who are trying to lose weight need a new approach that’s compatible with how we live today.
Specifically, most healthcare professionals and a majority of U.S. adults say losing weight is harder today than it was for previous generations because of the busy, modern lifestyle of Americans (77% of primary care physicians or PCPs, 81% of pharmacists, 62% U.S. adults). In fact, approximately seven in 10 healthcare professionals say it’s harder for Americans today to lose weight compared to just 10 years ago (69% of PCPs, 73% of pharmacists), and the vast majority believe Americans need to take a new approach to weight loss that fits with today’s modern lifestyle (89% of PCPs, 95% of pharmacists).
To view the multimedia release go to:
https://www.multivu.com/players/English/8215151-the-truth-about-weight-loss-national-survey/
Some say that when China sneezes the rest of the world catches cold, but the biggest luxury brands are catching on in China, becoming the most exclusive and desirable ones in fashion according to the wealthiest Chinese women. Still, our ranking also reveals a stronger competition that is accentuated by the wealthy customers’ increasingly stronger maturity. This barometer Promise Consulting / BNP Exane classifies the 15 most exclusive and desirable brands in China in the universe of feminine Fashion. This Barometer is conducted amongst the wealthiest Chinese women, and is about the 30 luxury brands in ready-to-wear/handbags/shoes/accessories that have invested the most in communication (source: Industry Interviews, Exane Paribas). Promise and BNP Exane already conducted the same survey amongst French women in May 2015 (http://bit.ly/1ESTZGu).
”This barometer in association with BNP Exane reflects our determination to move closer to the marketing and cross-section financial analysis. Our Monitoring Brand Assets® approach itself features very complementary analyzes with those conducted by BNP Exane’s experts. Hence, the obtained results from our joined barometer are based on two different angles of expertise, marketing and financial, which brings a unique added value to the managers and decision-makers in the Luxury sector. More concretely, our measure of the exclusivity of a brand takes into account the upper and more constant quality of products, the strong and unique valuation of the customer, the brand’s prestige, but also a matchless “savoir-faire” that justifies a very high price premium associated with top luxury. Finally, our measure of desirability synthesizes the dimensions of attractiveness of an intimate, social and symbolic nature, which are the strengths of exclusive brands, and characterize the particular relation that they maintain with their customers. In this respect, our Barometer synthesizes, in two proven scales, the numerous criteria to establish a ranking between the high-end brands from their customer’s point of view", states Pr. Philippe Jourdan, Promise’s CEO.
To view the multimedia release go to:
http://www.multivu.com/players/uk/7727851-exclusivity-desirability-luxury-brands/
Have you dreamed of a skincare product promising youth-preserving results only to be let down time and time again? Now you can make that dream a reality, as USANA launches its high-performance skincare system, Celavive®. This unique line is fueled by USANA InCelligence Technology®, a combination of powerful peptides, botanicals and key nutrients that talk to your skin’s cells to target your unique beauty needs.
As we age, our cellular function slows and becomes less effective, resulting in wrinkles and loss of firmness. By tapping into USANA InCelligence Technology, Celavive is able to signal your beauty-preserving functions to support your natural ability to retain moisture from within. It also supports other key elements that help contribute to a younger-looking complexion.
To view the multimedia release go to:
https://www.multivu.com/players/English/7736552-usana-celavive-skincare-line/
WebMD and Scripps Translational Science Institute (STSI) today announced a new investigative study designed to improve researchers’ and health care professionals’ understanding of what contributes to healthy pregnancies and positive pregnancy outcomes. The Healthy Pregnancy Study will use WebMD’s newly redesigned and enhanced Pregnancy app for iPhone. Incorporation of the Apple ResearchKit software framework will enable survey participants to eConsent, easily and anonymously answer questions, and share connected device data about their pregnancies with researchers for analysis.
“Pregnant women are one of the least studied populations in medical research,” said Dr. Eric Topol, director of STSI and editor-in-chief of Medscape. “The results of our Healthy Pregnancy Study -- on the foundation of an exceptionally popular smartphone app -- will ultimately provide expectant mothers, researchers, and health care professionals with new medical insights to avoid complications during pregnancy.”
To view the multimedia release go to:
https://www.multivu.com/players/English/7579757-webmd-stsi-healthy-pregnancy-study-app/
